医学诊所:分子肿瘤委员会
Precision Medicine Clinic: Molecular Tumor Board


精准医学诊所:分子肿瘤委员会通过一系列以病例为基础的研讨,帮助医师优化患者的分子诊断。《肿瘤学家》杂志鼓励相关研究机构分享发现和经验来帮助提高基因肿瘤学的精准度,改善患者结局。本合集精选了不同患者,展示了一系列肿瘤类型和突变情形,希望能够给您的临床实践带来相关获益

Precision Medicine Clinic: Molecular Tumor Board is a case-based series designed to help clinicians optimize molecular testing for their patients. The Editors of The Oncologist encourage institutions to share their findings and experiences to help improve the precision of genomic oncology and fulfill its promise of improved outcomes for patients. This collection highlights a diverse set of patients exhibiting a range of tumor types and mutations. We hope you find the clinical outcomes beneficial in your practice.


Understanding the Precision in “Precision Medicine”

Bruce A. Chabner
The Oncologist 2016; 21:1029-1030; first published on August 26, 2016;doi:10.1634/theoncologist.2016-0278


Durable Response to Nivolumab in a Pediatric Patient with Refractory Glioblastoma and Constitutional Biallelic Mismatch Repair Deficiency
Musa AlHarbi, Nahla Ali Mobark, Latifa AlMubarak, Rasha Aljelaify, Mariam AlSaeed, Amal Almutairi, Fatmah Alqubaishi, M. Emarat Hussain, Ali Abdullah O. Balbaid, Amal Said Marie, Lamia AlSubaie, Saeed AlShieban, Nada alTassan, Shakti H. Ramkissoon, Malak Abedalthagafi
The Oncologist first published on August 13, 2018;doi:10.1634/theoncologist.2018-0163

Tumor Molecular Testing Guides Anti‐PD‐1 Therapy and Provides Evidence for Pathogenicity of Mismatch Repair Variants
Shyam A. Patel, Teri A. Longacre, Uri Ladabaum, Alexandra Lebensohn, Albert Y. Lin, Sigurdis Haraldsdottir
The Oncologist first published on August 2, 2018;doi:10.1634/theoncologist.2018-0108

The Importance of Distinguishing Sporadic Cancers from Those Related to Cancer Predisposing Germline Mutations
Steven Sorscher
The Oncologist first published on June 4, 2018;doi:10.1634/theoncologist.2017-0681

EML4‐ALK Rearrangement and Its Therapeutic Implications in Inflammatory Myofibroblastic Tumors
Fernando Vargas‐Madueno, Edwin Gould, Raul Valor, Nhu Ngo, Linsheng Zhang, Miguel A. Villalona‐Calero
The Oncologist first published on May 8, 2018; doi:10.1634/theoncologist.2018-0014

Hybrid Capture‐Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1‐Mutant Cholangiocarcinoma Harboring a Novel YWHAZ‐BRAF Fusion
Huat C. Lim, Meagan Montesion, Thomas Botton, Eric A. Collisson, Sarah E. Umetsu, Spencer C. Behr, John D. Gordan, Phil J. Stephens, Robin K. Kelley
The Oncologist first published on April 5, 2018; doi:10.1634/theoncologist.2017-0645

Hybrid Capture‐Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1‐Mutant Cholangiocarcinoma Harboring a Novel YWHAZ‐BRAF Fusion
Don S. Dizon, Dora Dias‐Santagata, Amy Bregar, Laura Sullivan, Jennifer Filipi, Elizabeth DiTavi, Lucy Miller, Leif Ellisen, Michael Birrer, Marcela DelCarmen
The Oncologist first published on February 22, 2018; doi:10.1634/theoncologist.2017-0526

The Perils of Single‐Site Genetic Testing for Hereditary Cancer Syndromes in the Era of Next‐Generation Sequencing
Nicole Casasanta, Elizabeth Stark, Allison McHenry, Tara Biagi, Rebecca Kaltman
The Oncologist first published on February 14, 2018; doi:10.1634/theoncologist.2017-0372

Tumor Mutational Burden Guides Therapy in a Treatment Refractory POLE‐Mutant Uterine Carcinosarcoma
Munveer S. Bhangoo, Peter Boasberg, Pareen Mehta, Julia A. Elvin, Siraj M. Ali, Winnie Wu, Samuel J. Klempner
The Oncologist first published on January 31, 2018; doi:10.1634/theoncologist.2017-0342

Therapeutic Potential of Afatinib for Cancers with ERBB2 (HER2) Transmembrane Domain Mutations G660D and V659E
Hiromasa Yamamoto, Shinichi Toyooka, Takashi Ninomiya, Shigemi Matsumoto, Masashi Kanai, Shuta Tomida, Katsuyuki Kiura, Manabu Muto, Ken Suzawa, Patrice Desmeules, Mark G. Kris, Bob T. Li, Marc Ladanyi
The Oncologist 2018; 23:150-154; first published on November 16, 2017; doi:10.1634/theoncologist.2017-0345

Exceptional Response with Immunotherapy in a Patient with Anaplastic Thyroid Cancer
Revathi Kollipara, Bryan Schneider, Milan Radovich, Sunil Babu, Patrick J. Kiel
The Oncologist 2017; 22:1149-1151; first published on August 4, 2017; doi:10.1634/theoncologist.2017-0096

DNA Polymerase ɛ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity
Enrico Castellucci, Tianfang He, D. Yitzchak Goldstein, Balazs Halmos, Jennifer Chuy
The Oncologist 2017; 22:497-502; first published on May 2, 2017; doi:10.1634/theoncologist.2017-0034

Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center
Andrew Sharabi, Sangwoo Shawn Kim, Shumei Kato, Philip D. Sanders, Sandip Pravin Patel, Parag Sanghvi, Elizabeth Weihe, Razelle Kurzrock
The Oncologist 2017; 22:631-637; first published on May 26, 2017; doi:10.1634/theoncologist.2016-0517

A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases
Damato, Shannon Fogh, Emily K. Bergsland
The Oncologist 2017; 22:768-773; first published on May 15, 2017; doi:10.1634/theoncologist.2017-0054

Detection of an ALK Fusion in Colorectal Carcinoma by Hybrid Capture‐Based Assay of Circulating Tumor DNA
Andrea Z. Lai, Alexa B. Schrock, Rachel L. Erlich, Jeffrey S. Ross, Vincent A. Miller, Evgeny Yakirevich, Siraj M. Ali, Fadi Braiteh
The Oncologist 2017; 22:774-779; first published on May 15, 2017; doi:10.1634/theoncologist.2016-0376

ESR1突变的转移性乳腺癌:麻省总医院分子与精准医疗(MAP)肿瘤委员会的临床管理思考
Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital
Aditya Bardia, John A. Iafrate, Tilak Sundaresan, Jerry Younger, Valentina Nardi
The Oncologist 2016; 21:1035-1040; first published on August 22, 2016; doi:10.1634/theoncologist.2016-0240


Previous Collection


2017 Precision Medicine Clinic: Molecular Tumor Board